Every 10-Q that American Well Corporation (AMWL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMWL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMWL filings page.
American Well Corporation reported lower revenue but a much smaller loss for the quarter ended June 30, 2026. Revenue fell 27% year over year to $52.0 million, driven mainly by a drop in platform subscription fees (to $25.7 million) and “other” services and Carepoint device revenue, partly offset by higher visit revenue of $24.4 million.
Total costs and operating expenses declined 33% to $61.6 million as management reduced headcount across functions and cut consulting, marketing, and legal spend. Net loss attributable to Amwell narrowed to $9.9 million from $19.7 million, improving loss per share to $0.59 from $1.24. Adjusted EBITDA improved to a loss of $1.2 million from $4.7 million. For the first half of 2026, net loss attributable to Amwell was $20.8 million versus $38.4 million a year earlier.
Operating cash flow turned positive at $9.7 million for the six-month period, compared with a $29.8 million outflow in 2025, and cash, cash equivalents and restricted cash rose to $196.7 million. Results also reflect a $3.4 million impairment from abandoning the corporate headquarters right-of-use asset and a $7.0 million gain from contingent consideration on a prior divestiture. Client usage softened, with 1.9 million visits in the first half of 2026 versus 2.5 million a year earlier, and a single client represented 65% of accounts receivable, underscoring concentration risk.
American Well Corporation reported a smaller loss in Q1 2026 as cost cuts offset lower revenue. Revenue was $54.9 million, down 18% from $66.8 million a year ago, mainly from lower platform subscription and services revenue. Visit revenue rose to $28.9 million as more activity shifted to special program visits, with about 1.1 million total visits on the Amwell Platform.
Operating loss narrowed to $17.4 million from $30.4 million, helped by sharp reductions in research and development, sales and marketing, and general and administrative expenses after headcount cuts and other savings. Net loss attributable to Amwell improved to $10.9 million, or $(0.66) per share, from $(1.19) per share a year earlier. Adjusted EBITDA was a loss of $3.1 million, better than a $12.2 million loss in Q1 2025.
The company recorded a $7.0 million gain from contingent consideration tied to its prior APC divestiture and a $3.4 million impairment from abandoning its corporate headquarters lease. Amwell ended the quarter with $179.2 million in cash and cash equivalents, no debt, and used only $1.0 million of cash in operating activities.
American Well (AMWL) reported third‑quarter results for the period ended September 30, 2025. Revenue was $56.3 million, down from $61.0 million a year ago, as visit volumes declined while higher‑margin platform subscriptions grew. Loss from operations narrowed to $29.3 million from $47.4 million, reflecting lower costs across R&D, sales and marketing, and cost of revenue.
Platform subscription revenue rose to $30.9 million from $26.2 million, while visit revenue fell to $21.2 million from $27.5 million. Net loss attributable to the company improved to $32.4 million from $43.5 million; basic and diluted net loss per share was $2.00 versus $2.87. Cash, cash equivalents and restricted cash were $201.7 million as of September 30, 2025, compared with $245.4 million a year earlier. Operating cash use for the nine months was $48.6 million, an improvement from $113.9 million.
Year‑to‑date, the company recognized an $8.7 million gain from the January divestiture of its telepsychiatry APC Business. AMWL and Cleveland Clinic agreed to liquidate their CCAW joint venture, with remaining transition activities running through March 31, 2026. Deferred revenue ended at $32.0 million, down from $56.0 million as of December 31, 2024.
Selected financials (June 30, 2025)
Q2 revenue $70,898; three‑month net loss $19,531 (net loss attributable to American Well $19,696; EPS $(1.24)). Six months revenue $137,731; net loss $37,887 (attributable $38,400).
Balance sheet: cash and cash equivalents $219,072; total assets $388,656; total liabilities $94,083; total stockholders' equity $294,573; accumulated deficit $(2,004,326). Deferred revenue $43,259; transaction price allocated to remaining performance obligations $84,725 (71% expected in the 12 months ending June 30, 2026).
- Revenue mix: platform subscription $40,460; visits $22,752; other $7,686 (Q2).
- Divestiture: sale of APC business closed Jan 8, 2025; net proceeds reported $20,400 and a gain of $10,713 recognized in H1 2025.